BPC-157 is not FDA-approved. The current 503A regulation and interim categories do not establish an ordinary retail bulk-compounding route [11] [5]. FDA’s July briefing reports no approved product in its international search; that attributed finding is different from a current independent check of every country.
No established routine US pharmacy route for BPC-157
FDA approval and lawful pharmacy compounding are distinct routes for routine care. BPC-157 has no established route through either [3]. Investigational access follows separate requirements; registration alone does not establish those requirements have been met [1].
| Source | FDA-approved? | Quality checked by FDA? | A route for human use under FDA rules? | Note |
|---|---|---|---|---|
| Approved drug | None exists | Not applicable | No | FDA found no approved BPC-157 product in any country [3] |
| Compounding pharmacy | No | No | No routine bulk route established here | Current statutory/interim records do not establish ordinary retail bulk eligibility [11] |
| Telehealth prescription | No | No | Prescription alone is insufficient | Prescribing does not itself create a compounding exemption |
| Supplement capsules and tablets | No | No | Not established | Marketed as a supplement ingredient, per FDA; no USP supplement monograph [3] |
| "Research use only" vials | No | No | No | A label does not prove quality or authorize human treatment |
Status as of this update, from FDA's July 2026 briefing and its 503A lists.
A prescription alone does not establish legal supply
A 503A pharmacy may compound from a bulk ingredient only if it has a USP or NF monograph, is a component of an FDA-approved drug, or is on FDA's 503A bulks list [4]. BPC-157 has no monograph, is not part of any approved drug, and is not on the list [3]. The reviewed 503B nomination document also does not list BPC-157; nomination categories are not the same as a final bulks regulation or drug approval [6].
A prescription alone does not create a 503Aexemption. FDA’s briefing describes products already marketed in multiple forms and reports involving compounded injections; existence in commerce is not proof of approval, quality or lawful routine supply [3]. The FDA status review separates those questions.
| Date | What happened |
|---|---|
| May 14, 2026categories | BPC-157 is not in Category 1; withdrawn nominations do not confer approval [5] |
| July 2026briefing | FDA reviewers weigh against listing the nominated BPC substances [3] |
| Current 503A regulation | Section 216.23 lists six substances; BPC-157 is absent [11] |
| October 2026 OIRA entry | Peptide access notice pending review; not issued policy [2] |
What "research use only" means
A "research use only" label does not establish a product’s identity, quality or authorization for human treatment. FDA's review found "multiple salts, and derivatives, including different active moieties, sold commercially under the same common name" [3]. In plain terms, two vials labeled BPC-157 may not hold the same molecule. A seller label cannot establish the oversight, manufacturing controls or authorization required for a human investigation.
One adverse-event report FDA reviewed involved exactly this kind of product, a "research purposes only" vial that also contained TB-500; the person developed skin and gum darkening [3]. The wider safety picture is on whether BPC-157 is safe. The same research-use storefronts sell MOTS-c, and how FDA treats them is covered in whether you can buy MOTS-c legally.
BPC-157 capsules and supplements
FDA’s briefing describes marketed supplement capsules and tablets; that is not drugapproval or a determination that every marketed supplement is lawful [3]. An older oral trial registration has pharmacokinetic objectives but no posted results, and a newer gummy registration also has no results [12]. The route comparison explains the evidence limits.
What about BPC-157 with TB-500?
The TB-500 guide addresses a separate unapproved peptide. Full-length thymosin beta-4 and its fragment are different molecules; studies of one cannot establish the other’s safety or efficacy. A mixture also cannot identify which component caused an observed result. FDA’s current safety table separately names the fragment and BPC-157 [7].
Why there's no "best" BPC-157
This site does not rank retail BPC-157 offers. FDA’s product-identity and quality concerns and lack of approval prevent an efficacy or safety endorsement based on a seller’s description [3]. Our method explains why some compounds have evidence pages without seller recommendations.
What you can do instead
If you're looking at BPC-157 for an injury, joint pain or a gut problem, ask a clinician about FDA-approved treatments for that condition and whether a properly authorized clinical study is available. FDA noted that several approved drugs already treat ulcerative colitis, the condition it reviewed BPC-157 for [3].
Properly authorized investigational access is separate from retail treatment; a registry entry alone does not establish authorization [1]. As of this update ClinicalTrials.gov lists a randomized, placebo-controlled trial for hamstring strains recruiting in China [8], and a US trial after rotator cuff surgery that was not yet recruiting [9]. A clinician can help you search the registry for a trial that fits.
Athletes: it's prohibited at all times
WADA's Prohibited List names BPC-157 under S0, non-approved substances, prohibited in and out of competition [10]. A supplement that lists it as an ingredient carries the same risk for a tested athlete.
Research authorization differs from retail access
FDA’s IND framework separates investigational use from commercial marketing. It describes review of nonclinical safety, manufacturing and stability information, the clinical protocol, investigator qualifications, informed consent and ethics oversight [1]. A study record or the words “research use only” do not establish those requirements have been met.
The current registry includes an oral-gummy study marked completed with 40 actual participants over 8 weeks, but with no results posted and retrospective registration [13]. It demonstrates why “no human oral study exists” is too broad. It does not establish a clinical benefit, FDA approval, lawful retail availability or authorization of any other seller’s product.
For athletes, the exact 2026 WADA list names BPC-157 in S0, prohibited at all times [10]. That sports rule is a separate question from drugapproval, clinical benefit and permission to participate in a research study.